viewActinogen Medical Ltd

Actinogen Medical presenting successes with Xanamem at BIO International

Actinogen Medical Ltd (ASX:ACW) CEO and managing director Dr. Bill Ketelbey speaks to Proactive Investors about progress with its promising cortisol inhibitor, Xanamem.

“This is a drug very specifically designed to inhibit cortisol production in the brain, and the essence of that is that persistently raised cortisol has been shown to be associated with the development, and the progression, of Alzheimer’s disease. So our hypothesis is, if you inhibit that cortisol production in the brain you can impact - hopefully improve, hopefully moderate, hopefully stop - the development of Alzheimer’s disease, and that’s where we’re up to now. We are undertaking a large international trial to test that hypothesis,” explains Ketelbey.

The biotech company recently underwent an independent interim analysis of its phase II clinical trial for Xanamem in Alzheimer’s disease, named XanADu, which received the positive recommendation of continuation without modification.

Furthermore, Actinogen Medical recently attracted $17 million in funding from renowned institutional investors including Biotechnology Value Fund, Platinum Investment Management Limited and Australian Ethical Investment. Ketelbey describes it as, “a huge endorsement and validation of the trial, of the business, of the potential, and I guess of the management and science that sits behind it.”

This money will be invested in research into potential new indications for Xanamem. “There is a raft of additional opportunities that present themselves, so in a way Xanamem is a pipeline in a product. Alzheimer’s is the major target that we’re going for, but there’s depression, schizophrenia, Parkinson’s disease, epilepsy, potentially PTSD, post myocardial infarction, a whole raft of additional indications that we’ve been presented with. Probably the most developed and promising one is in diabetes... so as you can see it’s a broad platform of opportunities,” says Ketelbey.

Actinogen Medical will be presenting at BIO International in Boston, USA, next week.

Quick facts: Actinogen Medical Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $38.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Argo Blockchain CEO 'super optimistic on 2020' as it...

Argo Blockchain PLC's (LON:ARB) Peter Wall chats to Proactive London's Andrew Scott soon after assuming the role of CEO. He says they're ahead of schedule to reach their goal of 17,000 installed machines by the end of the first quarter of this year. ''2020 is really about optimising what...

13 hours, 23 minutes ago

2 min read